FEMASYS INC

Listed Company

FEMYCIK 0001339005NasdaqEmerging GrowthSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$2.29M

Net Income

$-18.63M

Total Assets

$20.72M

Equity

$5.87M

Shares Out

60.39M

Op. Cash Flow

$-18.69M

Business

FEMASYS INC is a biomedical company developing and commercializing minimally invasive diagnostic and therapeutic solutions addressing women’s reproductive health. Its main products and product candidates include FemaSeed for intratubal insemination, FemBloc non‑surgical permanent birth control with a degradable blended polymer, FemVue and FemChec companion ultrasound diagnostics, FemCath selective tubal catheter and FemCerv endocervical tissue sampler. Key business activities comprise clinical development, regulatory approvals, manufacturing and commercialization for infertility and contraception segments. Products are sold in the U.S. and through distributors in international markets including Europe, UK, Canada, Japan and Israel, with direct sales focused on North America.

Summary from filing dated 2025-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Sales	2	2	1	1	1
Cost of sales (excluding depreciation expense)	872,400	544,903	380,069	441,938	370,384
Research and development	8	8	7	6	4
Sales and marketing	4	4	650,126	558,852	208,735
General and administrative	7	6	7	5	4
Depreciation and amortization	342,034	297,318	483,481	561,233	591,068
Total operating expenses	19	19	15	12	9
Loss from operations	−18	−18	−15	−12	−8
Interest income	101,760	582,354	431,019	—	—
Change in fair value of conversion option liability	503,000	0	—	—	—
Change in fair value of warrants liabilities	731,000	0	—	—	—
Interest expense	−2	−2	−165,390	—	—
Other expense	−482,562	0	—	—	—
Total other expense, net	−1	−1	265,629	212,394	802,959
Loss before income taxes	−19	−19	−14	−11	−8
Income tax expense	1,297	9,602	4,338	6,300	4,000
Net loss	−19	−19	−14	−11	−8
Net loss attributable to common stockholders, basic	−19	−19	−14	−11	−8
Net loss attributable to common stockholders, diluted	−19	−19	−14	−11	−8
Net loss per share attributable to common stockholders, basic (in Dollars per share)	−0.47	−0.85	−0.93	−0.96	−1.12
Net loss per share attributable to common stockholders, diluted (in Dollars per share)	−0.47	−0.85	−0.93	−0.96	−1.12
Weighted-average common shares and pre-funded warrants outstanding- basic (in Shares)	40	22	15	12	7
Weighted-average common shares and pre-funded warrants outstanding- Diluted (in Shares)	40	22	15	12	7

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	9	3	22	13	25
Accounts receivable, net	616,600	488,373	98,906	77,470	84,258
Inventory	6	3	667,118	436,723	208,270
Prepaid and other current assets	833,133	1	695,879	655,362	555,853
Total current assets	16	8	23	14	26
Leasehold improvements	1	1	1	1	1
Office equipment	78,155	60,921	47,308	99,344	99,344
Furniture and fixtures	417,876	417,876	414,303	419,303	424,947
Machinery and equipment	3	3	3	3	2
Construction in progress	897,885	762,445	423,077	413,843	379,713
Property and equipment, gross	6	5	5	5	4
Less accumulated depreciation	−4	−4	−4	−3	−3
Net property and equipment	2	2	1	1	2
Lease right-of-use assets, net	1	2	2	—	—
Intangible assets, net of accumulated amortization	134,914	65,918	0	3,294	25,093
Other long-term assets	940,232	954,992	1	958,177	655,418
Total long-term assets	2	3	3	1	1
Total assets	21	12	28	17	29
Accounts payable	2	1	1	510,758	445,522
Accrued expenses	1	1	1	456,714	603,787
Convertible notes payable, net (including related parties)	0	5	0	—	—
Clinical holdback current portion	52,644	88,581	65,300	45,206	18,947
Operating lease liabilities current portion	487,624	517,967	406,636	—	—
Total current liabilities	4	9	3	2	2
Clinical holdback long-term portion	52,370	39,611	54,935	96,658	149,791
Convertible notes payable, net	3	0	4	0	—
Conversion option liability	2	0	—	—	—
Warrants liabilities	5	0	—	—	—
Operating lease liabilities long-term portion	1	2	2	—	—
Total long-term liabilities	11	2	6	125,242	552,208
Total liabilities	15	10	9	2	2
Commitments and contingencies	—	—	—	—	—
Common stock, $0.001 par, 200,000,000 authorized,59,720,010 shares issued and 59,602,787 outstanding as of December 31, 2025; and 23,473,149 shares issued and 23,355,926 outstanding as of December 31, 2024	59,720	23,473	21,775	11,987	11,921
Treasury stock, 117,223 common shares	−60,000	−60,000	−60,000	−60,000	—
Warrants	5	2	3	567,972	702,492
Additional paid-in-capital	146	128	124	109	108
Accumulated deficit	−146	−127	−108	−94	−83
Total stockholders equity	6	2	18	15	26
Total liabilities and stockholders' equity	21	12	28	17	29

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	295,859	277,178	480,187	539,434	551,092
Amortization	46,175	20,140	3,294	21,799	39,976
Other noncash items	5,724	0	—	—	—
Amortization of right-of-use assets	508,422	574,682	424,504	327,907	373,219
Loss on fixed asset dispositions	62,650	676	47,538	—	—
Share-based compensation expense	790,145	444,147	675,700	224,939	193,366
Amortization of debt issuance costs and discount	1	1	107,963	0	—
Accretion of paid-in-kind interest	132,140	0	—	—	—
Accounts receivable	−128,227	−389,467	−21,436	6,788	41,532
Inventory	−3	−2	−230,395	−232,553	−77,432
Prepaid and other assets	496,902	−139,136	282,169	295,862	475,993
Accounts payable	334,829	207,481	627,065	65,236	−228,811
Accrued expenses	474,724	6,753	987,582	−147,073	−504,799
Lease liabilities	−517,967	−406,636	−440,489	−383,616	−413,212
Other liabilities	−23,178	−36,568	22,896	−62,911	−25,987
Net cash used in operating activities	−19	−19	−11	−11	−8
Acquisition of patents	−105,091	−86,058	0	—	0
Purchases of property and equipment	−525,007	−761,706	−143,917	−407,475	−306,868
Net cash used in investing activities	−630,098	−847,764	−143,917	−407,475	−306,868
Proceeds from exercise of pre-funded warrants	500	0	188	0	—
Proceeds from exercise of common warrants	3	0	4	0	—
Proceeds from November 2025 convertible notes	12	0	7	0	—
Issuance costs for November 2025 convertible notes	−718,528	0	—	—	—
Proceeds from common stock issued through ESPP	90,332	63,106	4,955	19,880	—
Proceeds from at-the-market sales of common stock	7	2	—	—	—
Issuance costs for at-the-market sales of common stock	−210,395	−60,753	—	—	—
Repayment of November 2023 convertible notes, including related parties	−7	0	−525,144	0	—
Repayment of note payable	−367,450	0	−610,340	−505,205	−442,086
Net cash provided by financing activities	25	2	20	−681,645	30
Net change in cash and cash equivalents	6	−18	9	−12	21
Interest	8,615	111,000	9,903	13,464	15,865
Income taxes	6,806	5,708	4,550	5,050	800
Property and equipment costs included in accounts payable and accrued expense	60,447	73,740	—	—	—
Acquisition of patents included in accounts payable	15,804	0	—	—	—
Conversion of November 2023 convertible notes into common stock	85,000	0	—	—	—
Payment of November 2023 convertible note interest in common stock	360,000	300,000	0	—	—
Deferred offering costs reclassified to additional paid-in-capital	15,637	3,143	17,952	95	—
Fair value of conversion option liability at November 2025 issuance	3	0	—	—	—
Fair value of warrants liabilities at November 2025 issuance	6	0	2	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro